Showing results (2091-2100 of 2,317) with videos related to
Sort By:
Pageof 232
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407Steven F Powell, Delvys Rodríguez-Abreu, Corey J Langer, et al.Journal of Proteome Research|May 17, 2014
Chromosome-centric Human Proteome Project (C-HPP): Chromosome 12Sakdithep Chaiyarit, Nilubon Singhto, Yi-Ju Chen, et al.Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.Chinese Medical Journal|July 21, 2022
A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patientsXiang Zheng, Weijie Zhang, Hua Zhou, et al.Innovation (Cambridge (Mass.))|January 28, 2025
Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket studyLuoyan Ai, Qian Li, Shilong Zhang, et al.Sports Medicine and Health Science|June 30, 2021
The COVID-19 pandemic and physical activityJeffrey A Woods, Noah T Hutchinson, Scott K Powers, et al.JAMA Oncology|August 12, 2018
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical TrialBaohui Han, Kai Li, Qiming Wang, et al.Journal for Immunotherapy of Cancer|February 22, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialShengxiang Ren, Xicheng Wang, Bao-Hui Han, et al.The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.Pageof 232